Why Teladoc Stock Is Plummeting Today
Teladoc (TDOC -11.83%) stock is sinking in Thursday's trading on the heels of the company's recent fourth-quarter release. The telehealth specialist's share price was down 11.7% as of 2:45 p.m.
Teladoc Q4 Earnings: A Waiting Game For Investors (Rating Downgrade)
Teladoc Health, Inc.'s disappointing guidance and lack of revenue growth have led me to adopt a neutral stance on TDOC stock despite its cheap valuation at 7x forward free cash flow. My investment strategy focuses on businesses with strong balance sheets and the potential for significant free cash flow growth, but Teladoc's fundamentals don't align with this narrative. Teladoc's manageable debt and plans to retire convertible debt improve its financial footing, but I need to see revenue momentum before considering it investable again.
Teladoc Health, Inc. (TDOC) Q4 2024 Earnings Call Transcript
Teladoc Health, Inc. (NYSE:TDOC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Minchak - Head of Investor Relations Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Lisa Gill - J.P. Morgan Jessica Tassan - Piper Sandler David Roman - Goldman Sachs Sean Dodge - RBC Richard Close - Cannacord Genuity Daniel Grosslight - Citi Jailendra Singh - Truist George Hill - Deutsche Bank Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Operator Good afternoon and thank you all for attending the Teladoc Health Q4 2024 Earnings Call.
Here's What Key Metrics Tell Us About Teladoc (TDOC) Q4 Earnings
While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates
Teladoc (TDOC) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.17 per share a year ago.
Teladoc's Earnings Miss as Revenue Falls
Teladoc Health (TDOC -1.70%), a leader in telehealth services, released its fourth-quarter earnings on Feb. 26. The company reported revenue of $640.5 million, just above the $639 million that analysts had expected, but 3% lower than the same quarter last year.
Teladoc shares tumble on wider-than-expected loss, disappointing revenue guidance
Teladoc Health shares fell in extended trading on Wednesday after the company issued weak guidance and reported a bigger loss than expected. Revenue at the telehealth company decreased 3% in the fourth quarter to $640.5 million.
What Analyst Projections for Key Metrics Reveal About Teladoc (TDOC) Q4 Earnings
Evaluate the expected performance of Teladoc (TDOC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Teladoc Health: Needs A Growth Catalyst
Teladoc Health is a beaten-down stock with stagnant revenue, priced attractively relative to its sector. Momentum for this stock has been building up as value investors anticipate a reversal. This momentum came after the company announced an AI product that will help physicians monitor their patients' movements remotely. In this article, I lay out my take on the stock, why I think conservative investors might have to wait for the growth catalyst before hitting that buy button.
Is Teladoc Stock a Buy?
Teladoc Health (TDOC 6.07%), the famed telemedicine specialist that rose to prominence in the early pandemic years, is not performing nearly as well as it once did. Over the past three years, the company's financial results have been disappointing -- at best -- and its stock price has plummeted.
Citron Research Just Called This "Pandemic Relic" Stock a Hidden Artificial Intelligence (AI) Opportunity. Time to Buy?
When analyzing stocks, listening to interviews or reading reports conducted by equity research analysts on Wall Street can be helpful. Personally, I find augmenting my own research with the findings of industry experts pretty valuable, as it helps build a more inclusive, well-rounded view of a business.
The Big 3: KC, TDOC, RDDT
From consolidation to explosive climbs, Aquiles Larrea turns to stocks that he believes are poised for more breakout opportunity. He turns to bullish indicators behind Kingsoft (KC), Teladoc Health (TDOC) and Reddit (RDDT).
